



06-18-01

# 7

0360  
Box seg

EXPRESS MAIL EL 915668745 US Deposited: June 15, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service Express mail under 37 CFR 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, DC 20231

*Kelly Morris*

/ Kelly Morris Date: 06/15/01

Docket No. JG-EPC-4955/500563.20013

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Agamemnon Antoniou EPENETOS Group: Unassigned

Serial No.: 09/819,266 Examiner: Unassigned

Filed: March 28, 2001

For: COMPOUNDS FOR TARGETING

Commissioner of Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

S I R:

In order to fulfill the requirements of candor and good faith set forth in 37

C.F.R. § 1.56, Applicant submits this Information Disclosure Statement in accordance with

the provisions of 37 C.F.R. §§ 1.97 and 1.98.

**FOREIGN PATENTS:**

<u>Patent No.:</u>	<u>Publication Date:</u>	<u>Country:</u>
0 302 473 A2	Feb. 2, 1989	EPO
0 781 845 A2	July 2, 1997	EPO
2289679 A	July 21, 1994	Great Britain
88/07378 A1	October 6, 1988	PCT
92/04380 A1	March 19, 1992	PCT
94/11508 A2	May 26, 1994	PCT
98/08957 A1	March 5, 1998	PCT
99/29721 A1	June 17, 1999	PCT
99/35277 A2	July 15, 1999	PCT
91/11201 A2	August 8, 1991	PCT



#### NON-PATENT REFERENCES:

1. Alnemri et al., "Human ICE/CED-3 Protease Nomenclature," *Cell*, 87, p. 171 (1996);
2. Ashkenazi et al., "Death Receptors: Signaling and Modulation," *Science*, 281, pp. 1305-1308 (1998);
3. Bagshawe, "Antibody Directed Enzymes Revive Anti-Cancer Prodrugs Concept," *Br. J. Cancer*, 56, pp. 531-532 (1987);
4. Bagshawe et al., "A Cytotoxic Agent Can Be Generated Selectively At Cancer Sites," *Br. J. Cancer*, 58, pp. 700-703 (1988);
5. Benjamin et al., "Caspase Activation In MCF7 Cells Responding To Etoposide Treatment," *Mol. Pharmacol.*, 53, pp. 446-450 (1998);
6. Burchell et al., "Development And Characterization Of Breast Cancer Reactive Monoclonal Antibodies Directed To The Core Protein Of The Human Milk Mucin," *Cancer Res.*, 47, pp. 5476-5482 (1987);
7. Clark et al., "Role Of The Bp35 Cell Surface Polypeptide In Human B-Cell Activation," *Proc. Natl. Acad. Sci. USA*, 82, pp. 1766-1770 (1985);
8. Cohen, "Caspases: The Executioners Of Apoptosis," *Biochem. J.*, 326, pp. 1-16 (1997);
9. Colcher et al., "In Vivo Tumor Targeting Of A Recombinant Single-Chain Antigen-Binding Protein," *J. Nat. Cancer Inst.*, 82, pp. 1191-1197 (1990);
10. Deonarain et al., "Redesigned Anti-Human Placental Alkaline Phosphatase Single-Chain Fv: Soluble Expression, Characterization And *In Vivo* Tumour Targeting," *Protein Engin.*, 10: 1, pp. 89-98 (1997);
11. Enari, et al., "A Caspase-Activated Dnase That Degrades DNA During Apoptosis, And Its Inhibitor ICAD," *Nature*, 391, pp. 43-50 (1998);
12. Frankel et al., "Modulation Of The Apoptotic Response Of Human Myeloid Leukemia Cells To A Diphtheria Toxin Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein," *Blood*, 90: 9, pp. 36454-3661 (1997);
13. Fernandes-Alnemri et al., "*In Vitro* Activation Of CPP32 And Mch3 By Mch4, A Novel Human Apoptotic Cystein Protease Containing Two FADD-Like Domains," *Proc. Natl. Acad. Sci. USA*, 93, pp. 7464-7469 (1996);
14. Gurtu et al., "Fluorometric And Colorimetric Detection Of Caspase Activity Associated With Apoptosis," *Anal. Biochem.*, 251, pp. 98-102 (1997);
15. Hellström et al., "Monoclonal Mouse Antibodies Raised Against Human Lung Carcinoma," *Cancer Res.*, 46, pp. 3917-3923 (1986);
16. Hnatowich et al., "Patient Biodistribution Of Intraperitoneally Administered Yttrium-90-Labeled Antibody," *J. Nucl. Med.*, 29, pp. 1428-1434 (1998);
17. Hu et al., "Caspase-14 Is A Novel Developmentally Regulated Protease," *J. Biol.*

- Chem.*, 273: 45, pp. 29648-53 (1998);
18. Humke et al., "ERICE, A Novel FLICE-Activatable Caspase," *J. Biol. Chem.*, 273:25, pp. 15702-7 (1998);
  19. Kalofonos et al., "Imaging Of Tumor In Patients With Indium-111-Labeled Biotin And Streptavidin-Conjugated Antibodies: Preliminary Communication," *J. Nucl. Med.*, 31: 11, pp. 1791-1796 (1990);
  20. Kamada et al., "Caspase-4 And Caspase-5, Members Of The ICE/CED-3 Family Of Cysteine Proteases, Are Crma-Inhibitable Proteases," *Cell Death and Differentiation*, 4, pp. 473-478 (1997);
  21. Kamada et al., "Involvement Of Caspase-4(-Like) Protease In Fas-Mediated Apoptotic Pathway," *Oncogene*, 15, pp. 285-90 (1997);
  22. Kischkel et al., "Cytotoxicity-Dependent APO-1 (Fas/CD95)-Associated Proteins Form A Death-Inducing Signaling Complex (DISC) With The Receptor," *The EMBO J.*, 14: 22, pp. 5579-5588 (1995);
  23. LeBlanc et al., "Caspase-6 Role In Apoptosis Of Human Neurons, Amyloidogenesis, And Alzheimer's Disease," *J. Biol. Chem.*, 274: 33, pp. 23426-36 (1999);
  24. Li et al., "Activation Of Caspase-2 In Apoptosis," *J. Biol. Chem.*, 272: 34, pp. 21010-7 (1997);
  25. Loke et al., "Cytotoxic T Lymphocytes Can Induce A Condemned State And Synchronous Post-Mitotic Apoptosis Of Daughter Target Cells," *Eur. J. Immunol.*, 29, pp. 1793-1802 (1999);
  26. Marcelli et al., "Caspase-7 Is Activated During Lovastatin-Induced Apoptosis Of The Prostate Cancer Cell Line LNCap," *Cancer Res.*, 58, pp. 76-83 (1998);
  27. Muzio et al., "An Induced Proximity Model For Caspase-8 Activation," *J. Biol. Chem.*, 273: 5, pp. 2926-2930 (1998);
  28. Nakagawa et al., "Caspase-12 Mediates Endoplasmic-Reticulum-Specific Apoptosis And Cytotoxicity By Amyloid-B," *Nature*, 403, pp. 98-103 (2000);
  29. Namura et al., "Activation And Cleavage Of Caspase-3 In Apoptosis Induced By Experimental Cerebral Ischemia," *J. Neurosci.*, 18: 10, pp. 3659-3668 (1998);
  30. Ng et al., "Molecular Cloning And Characterization Of Two Novel Pro-Apoptotic Isoforms Of Caspase-10," *J. Biol. Chem.*, 274: 15, pp. 10301-10308 (1999);
  31. Nicholson et al., "Caspases: Killer Proteases," *Trends Biochem. Sci.*, 257, pp. 299-306 (1997);
  32. Ohta et al., "Video-Enhanced Microscopic Visualization Of Apoptotic Cell Death Caused By Anti-Fas Antibody In Living Human Glioma Cells," *Brain Tumor Pathol.*, 15, pp. 19-21 (1998);
  33. Paganelli et al., "Intraperitoneal Radio-Localization Of Tumors Pre-Targeted By Biotinylated Monoclonal Antibodies," *Int. J. Cancer*, 45, pp. 1184-1189 (1990);
  34. Reed, "Dysregulation Of Apoptosis In Cancer," *J. Clin. Oncol.*, 17: 9, pp. 2941-2953 (1999);


35. Rotonda et al., "The Three-Dimensional Structure Of Apopain/CPP32, A Key Mediator Of Apoptosis," *Nat. Struct. Biol.*, 3: 7, pp. 619-25 (1996);
36. Rybak et al., "Cytotoxic Potential Of Ribonuclease And Ribonuclease Hybrid Proteins," *J. Biol. Chem.*, 266: 31, p. 21202-7 (1991);
37. Scaffidi et al., "FLICE Is Predominantly Expressed As Two Functionally Active Isoforms, Caspase-8/A And Caspase-8/B," *J. Biol. Chem.*, 272: 43, pp. 26953-8 (1997);
38. Senter et al., "Anti-Tumor Effects Of Antibody-Alkaline Phosphatase Conjugates In Combination With Etoposide Phosphate," *Proc. Natl. Acad. Sci. USA*, 85, p. 4842-4846 (1988);
39. Srinivasa et al., "Generation Of Constitutively Active Recombinant Caspases-3 And -6 By Rearrangement Of Their Subunits," *J. Biol. Chem.*, 273: 17, pp. 10107-10111 (1996);
40. Srinivasa et al., "Molecular Ordering Of The Fas-Apoptotic Pathway: The Fas/APO-1 Protease Mch5 Is A CrmA-Inhibitable Protease That Activates Multiple Ced-3/ICE-Like Cysteine Proteases," *Proc. Natl. Acad. Sci. USA*, 93, pp. 14486-14491 (1996);
41. Thornberry et al., "A Novel Heterodimeric Cysteine Protease Is Required For Interleukin-1 Processing In Monocytes," *Nature*, 356, pp. 768-774 (1992);
42. Thornberry et al., "A Combinatorial Approach Defines Specificities Of Members Of The Caspase Family And Granzyme B," *J. Biol. Chem.*, 272: 19, pp. 17907-17911 (1997);
43. Vakkala et al., "Expression Of Caspases 3, 6 And 8 Is Increased In Parallel With Apoptosis And Histological Aggressiveness Of The Breast Lesion," *Br. J. Cancer*, 81: 4, pp. 592-599 (1999);
44. Wang et al., "Murine Caspase-11, An Ice-Interacting Protease, Is Essential For The Activation Of Ice," *Cell*, 92, pp. 501-9 (1998);
45. Weissner et al., "Quantification Of Apoptotic And Lytic Cell Death By Video Microscopy In Combination With Artificial Neural Networks," *Cytometry*, 31, pp. 20-28 (1998);
46. Wilson et al., "Structure And Mechanism Of Interleukin-1 Converting Enzyme," *Nature*, 370, pp. 270-274 (1994);
47. Wolf et al., "Suicidal Tendencies: Apoptotic Cell Death By Caspase Family Proteinases," *J. Biol. Chem.*, 274: 29, pp. 20049-20052 (1999);
48. Yang et al., "Autoproteolytic Activation Of Pro-Caspases By Oligomerization," *Mol. Cell.*, 1, pp. 319-325 (1988); and
49. Yokota et al., "Rapid Tumor Penetration Of A Single-Chain Fv And Comparison With Other Immunoglobulin Forms," *Cancer Res.*, 52, pp. 3402-3408 (1992).

The above-listed references are also listed in Form PTO-1449 which is enclosed herewith.

This submission is not an admission that the information disclosed in any of the references is material to the patentability of the invention disclosed and/or claimed in the above-identified application. Accordingly, Applicant respectfully submits that the application is in all respects in condition for examination on the merits.

The Commissioner is hereby authorized to charge any fees in connection herewith to Deposit Account No. 50-1529.

Respectfully submitted,

  
Jules E. Goldberg - Reg. No. 24,408  
Reed Smith LLP  
375 Park Avenue  
New York, NY 10152  
Tel. (212) 521-5400

JEG/SRP/km  
06/15/01

Enclosures:  
PTO-1449 w/59 references